Patient Opportunity: Share Your Experience with TALZENNA® + XTANDI®

Pfizer is seeking individuals with HRR-mutated metastatic castration-resistant prostate cancer (mCRPC) who are currently taking TALZENNA® (talazoparib) + XTANDI® (enzalutamide), along with their care partners, to share their experiences as part of patient education initiatives.

Selected participants may have the opportunity to participate in videos, interviews, or other educational materials and will be compensated for their time.

If you're interested in learning more or finding out if you qualify, please refer to the information on the attached recruitment card to contact Snow Companies directly.

As part of our commitment to keeping the prostate cancer community informed, PCRI is sharing this opportunity as a resource for eligible patients and care partners. PCRI does not endorse any specific treatment, product, or sponsored program.